Simris Alg aktie (SIMRIS B) | Pressmeddelande - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

•Kom igång: Så börjar du spara i fonder 2025 – bästa tipsen för att komma igång (stor guide)

Pressmeddelanden från Simris Alg

 Bevaka pressreleaser
Kurs från TradingView
StartNyheterPressreleaserRiktkurserInsynshandelBlankningAnalyserBloggarVideosPodcasts

Notice of Extraordinary General Meeting of Simris Group AB (publ)

English version follow after the Swedish version.

MFN • 23 Dec 11:07

Simris resolves on a share issue, repayment of convertible debentures, prolongation of loan agreements, entering into and to call for a general meeting to resolve to enter into new loan agreements

Simris Group AB (publ) (“Simris Group” or the “Company”) today announces that the board of directors has resolved on a financing package in ...

MFN • 23 Dec 09:44

SIMRIS GROUP INTERIM REPORT JANUARY-SEPTEMBER 2024

SIMRIS GROUP INTERIM REPORT JANUARY-SEPTEMBER 2024

MFN • 13 Nov 08:00

Uncertainty regarding when the next payment from the agreed loan facility can occur

Simris Group AB (publ) (“Simris Group” or the “Company”) announced today that payments from the previously announced and agreed loan facilit...

MFN • 23 Oct 18:04

Simris Group chairman and major owner Steven Schapera has passed away after complications after surgery

Simris Group announces that the company's major owner and chairman Steven Schapera has passed away after complications after surgery.

MFN • 18 Oct 18:22

Simris Biologics awarded funding for a research collaboration with Berlin's University of Applied Science to explore the ability of natural compounds from Cyanobacteria to delay aging

Simris Group AB (publ) ("Simris Group" or the "Company") confirms that its wholly owned Berlin-based subsidiary Simris Biologics GmbH, in co...

MFN • 09 Sep 08:00

SIMRIS GROUP INTERIM REPORT JANUARY-JUNE 2024

SIMRIS GROUP INTERIM REPORT JANUARY-JUNE 2024

MFN • 14 Aug 08:00

Simris Biologics enters into a collaboration agreement with New Zealand Universities to develop peptide drug conjugates (PDC)

Simris Group AB (publ) ("Simris Group" or the "Company") today confirms that its wholly owned Berlin-based subsidiary, Simris Biologics GmbH...

MFN • 09 Jul 15:45

Bulletin from Simris Group AB (publ)’s Annual General Meeting

Simris Group AB (publ), reg. no. 556841–9187 (the "Company"), held its annual general meeting on 28 June 2024.

MFN • 28 Jun 11:15

Notice of the Annual General Meeting of Simris Group AB (publ)

English version follow after the Swedish version.

MFN • 27 May 18:35

SIMRIS GROUP INTERIM REPORT JANUARY-MARCH 2024

SIMRIS GROUP INTERIM REPORT JANUARY-MARCH 2024

MFN • 15 May 08:00

SIMRIS GROUP AB ANNOUNCED TODAY THAT THE BOARD HAS DECIDED TO MOVE THE COMPANY'S ANNUAL GENERAL MEETING FROM MAY 29, 2024 TO JUNE 28, 2024

SIMRIS GROUP AB ANNOUNCED TODAY THAT THE BOARD HAS DECIDED TO MOVE THE COMPANY'S ANNUAL GENERAL MEETING FROM MAY 29, 2024 TO JUNE 28, 2024

MFN • 29 Apr 14:00

Simris Group AB (publ) announces the outcome of the directed offer of convertible debentures

Simris Group AB (publ) (“Simris Group” or the “Company”) today announces that the directed issue of convertible debentures (the “Convertible...

MFN • 23 Apr 14:10

SIMRIS GROUP PUBLISHES ITS ANNUAL REPORT FOR 2023

Simris Group AB has published its annual report for the 2023 financial year.

MFN • 17 Apr 14:45

SIMRIS GROUP CONFIRMS A TERM EXTENSION TO FLEXIBLE FUNDING FACILITY

Simris Group AB and The Brand Laboratories FZ have agreed to extend the term of the existing flexible funding facility.

MFN • 15 Apr 20:30

Bulletin from Simris Group’s Extraordinary General Meeting

Simris Group AB (publ), reg. no. 556841–9187 (the "Company") held an extraordinary general meeting on 5 April 2024.

MFN • 05 Apr 11:15

Notice of Extraordinary General Meeting of Simris Group AB (publ)

English version follow after the Swedish version.

MFN • 19 Mar 19:33

The board of Simris Group AB (publ) resolves to change the terms of the directed issue of convertible debentures by increasing from EUR 1.0m to EUR €1.15m subject to the approval of the general meeting.

The board of directors of Simris Group AB (publ) (“Simris Group” or the “Company”) has today resolved to change the terms of the directed is...

MFN • 15 Mar 21:34

The board of Simris Group AB (publ) resolves on a directed issue of convertible debentures up to EUR 1,000,000 subject to the approval of the General Meeting.

The board of directors of Simris Group AB (publ) (“Simris Group” or the “Company”) has today resolved on a directed issue of convertible deb...

MFN • 14 Mar 18:35

Julian Read steps down as CEO of Simris Group. The Board of Simris appoints Dr Alexis Roberts-McIntosh as his successor with immediate effect.

Simris Group AB has today, March 12th, 2023, announced the appointment of Dr.

MFN • 12 Mar 21:10

Simris Group AB confirms that it will temporarily pause production at its facility in Hammenhög, Sweden

The Simris Board of Directors have resolved to temporarily pause production operations at its microalgae facility in Hammenhög, Sweden.

MFN • 06 Mar 09:02

SIMRIS GROUP YEAR-END REPORT JANUARY-DECEMBER 2023

SIMRIS GROUP YEAR-END REPORT JANUARY-DECEMBER 2023

MFN • 28 Feb 08:00

Simris signs Head of Terms for an offtake agreement valued at minimum €2m / SEK 22m

Simris Group AB (publ) ("Simris" or the "Company") today confirms that it has signed a non-binding Heads of Terms (HOT) agreement with an ex...

MFN • 10 Jan 08:00

Bulletin from Simris Group’s Extraordinary General Meeting

Simris Group AB (publ), reg. no. 556841–9187 (the "Company") held an extraordinary general meeting on 20 December 2023.

MFN • 20 Dec 2023 10:45

Simris Biologics signs Material Transfer Agreement with pre-clinical biotech company to develop Linker-Payloads

Simris Group AB (publ) ("Simris Group" or the "Company") today confirms that its subsidiary company, Simris Biologics GmbH, has signed a Mat...

MFN • 20 Dec 2023 09:45

Notice of Extraordinary General Meeting of Simris Group AB (publ)

Simris Group AB (publ), reg. no. 556841–9187 (the "Company") will hold an extraordinary general meeting on 20 December 2023 at 10:15.

MFN • 01 Dec 2023 16:01

The board of Simris Group AB (publ) proposes a directed share issue of approximately MSEK 1.55

The board of directors of Simris Group AB (publ) ("Simris Group" or the "Company") proposes that a general meeting on 20 December 2023 resol...

MFN • 01 Dec 2023 16:00

Simris Biologics awarded €163,000 for the genetic engineering of cyanobacterial strains during an 18-month project beginning January 2024

Simris Group AB (publ) ("Simris Group" or the "Company") today confirms that its wholly owned subsidiary Simris Biologics GmbH based in Berl...

MFN • 15 Nov 2023 14:15

Simris Group: Interim Report January - September 2023

Simris Group: Interim Report January - September 2023

MFN • 08 Nov 2023 08:00

Simris appoints a distribution partner for Omega-3 products in North America delivering revenue of approx., €60k, and annual cost savings of €200k

Simris Group AB (publ) ("Simris Group" or the "Company") today confirms that it has appointed Reviate LLC (www.

MFN • 07 Nov 2023 15:30

Simris Group AB completes a directed share issue of approximately 3 MSEK to strategic investors

The board of directors of Simris Group AB (publ) ("Simris Group" or the "Company") has today, based on the authorisation from the annual gen...

MFN • 29 Oct 2023 19:55

Last day of trading with BTA in Simris Group

The fully guaranteed rights issue (“Rights Issue”) and the directed issue ("Directed Issue") in Simris Group AB (publ) (“Simris Group” or th...

MFN • 11 Sep 2023 14:40

Simris Group AB (Publ) announces the final outcome of the fully secured Rights Issue

The Board of Directors of Simris Group AB (publ) (“Simris Group” or "Company") announces the outcome of the Rights Issue of shares with pref...

MFN • 18 Aug 2023 19:32

Preliminary subscription rate of Rights Issue in Simris Group AB (Publ) amounts to approximately 57 percent

The preliminary outcome of the Rights Issue in Simris Group AB (publ) (“Simris Group” or the “Company”), the subscription period of which en...

MFN • 16 Aug 2023 18:15

BioStock: Emission ska ta Simris Group till första licensavtalet

Under 2022 inledde Simris Group en satsning som ska göra bolaget till ett lönsamt biofarmabolag.

Cision • 11 Aug 2023 08:25

Simris Group CEO, Julian Read, svarar på frågor från Finwire angående företagets strategi och den pågående företrädesemissionen

Julian Read, VD för Simris Group AB klargör det strategiska fokuset för Bolaget, affärsmodellen för dess Antibody Drug Conjugate (ADC)-produ...

MFN • 08 Aug 2023 14:15

SIMRIS GROUP SIGNS LETTER OF INTENT TO SECURE INDUSTRIAL SCALE PRODUCTION CAPACITY THROUGH COMMERCIAL PARTNERSHIP

Simris has signed a Letter of Intent (LOI) to secure the production of microalgae biomass via a manufacturing collaboration agreement with P...

MFN • 04 Aug 2023 14:55

Simris Biologics confirms new patent application from its ADC-payload platform

Simris Biologics confirms it has submitted a new patent application covering the optimisation of microcystin-based Antibody Drug Conjugate (...

MFN • 02 Aug 2023 16:00

Simris Group AB publishes information memorandum for the Rights Issue

Simris Group AB (“Simris Group” or the “Company”) today, on July 31, 2023, announces the information memorandum relating to the Company's up...

MFN • 31 Jul 2023 19:15

Simris Group presents a forward-looking statement and a financial forecast for its subsidiary Simris Biologics

Simris Group forecasts that Simris Biologics will generate annual sales revenue of €3.

MFN • 31 Jul 2023 16:55

Simris Group strengthens its management team

Simris Group confirms that Dr Heike Enke, Chief Science Officer for non-ADC Technologies within Simris Biologics, will, as of 31st July, be ...

MFN • 28 Jul 2023 17:30

Simris Group confirms 100% underwritten rights issue

Simris Group confirms that 100 % of its upcoming SEK 24,3 million rights issue now is underwritten with 8,8 precent in subscription commitme...

MFN • 27 Jul 2023 12:00

Bulletin from the Extraordinary General Meeting

Simris Group AB (the "Company") held an extraordinary general meeting on 24 July 2023.

MFN • 24 Jul 2023 10:51

Simris Group Interim Report January-June 2023

Simris Group Interim Report January-June 2023

MFN • 24 Jul 2023 08:00

Correction: Simris Group presents a letter from the CEO

This letter from Julian Read, CEO of Simris Group AB, shares his thoughts around the transformation of the company from a struggling Omega-3...

MFN • 18 Jul 2023 12:15

VD för Simris Group AB, Julian Read, presenterar sina tankar kring företagets framtid

I detta brev delar Julian med sig av sina tankar kring omvandlingen av företaget från en tuff kamp att bryta ny mark för Omega-3 till ett sp...

MFN • 17 Jul 2023 21:35

Kallelse till extra bolagsstämma i Simris Group AB (publ)

Simris Group AB (publ), org.nr 556841–9187 (”Bolaget”) håller extra bolagsstämma den 24 juli 2023 klockan 10.

MFN • 05 Jul 2023 22:28

SIMRIS GROUP TIDIGARELÄGGER DELÅRSRAPPORT FÖR KVARTAL 2

Simris Group meddelar härmed att publiceringen av bolagets delårsrapport för andra kvartalet 2023, perioden 1 januari - 30 juni 2023, kommer...

MFN • 05 Jul 2023 22:22

Simris styrelse föreslår att en bolagsstämma beslutar om en företrädesemission om högst ca 24,3 MSEK och en aktieägare föreslår en riktad emission om högst ca 26,6 MSEK

Styrelsen för Simris Group AB (publ) (“Simris Group” eller ”Bolaget”) föreslår att en extra bolagsstämma (den ”Extra Bolagsstämman”) besluta...

MFN • 05 Jul 2023 22:19

SIMRIS GROUP BEKRÄFTAR EN FÖRLÄNGNING AV FLEXIBEL FINANSIERINGSFACILITET

Villkorat av aktieägarnas godkännande vid en extra bolagsstämma har Simris Group AB och The Brand Laboratories FZ kommit överens om att förl...

MFN • 05 Jul 2023 22:13

KOMMUNIKÉ FRÅN ÅRSSTÄMMA I SIMRIS GROUP AB

Simris Group AB ("Bolaget") höll Årsstämma den 29 maj 2023.

MFN • 29 May 2023 11:55

SIMRIS GROUP DELÅRSRAPPORT JANUARI-MARS 2023

SIMRIS GROUP DELÅRSRAPPORT JANUARI-MARS 2023

MFN • 08 May 2023 08:00

SIMRIS GROUP AB BEKRÄFTAR EN FÖRLÄNGNING AV FÖRFALLODATUM FÖR DEN ANDRA DELEN FÖR FÖRVÄRVET AV CYANO BIOTECH OCH EN FÖRLÄNGNING AV FINANSIERINGSFACILITET FRÅN THE BRAND LABORATORIES

Simris Group AB (publ), bekräftar att styrelsen har godkänt ett erbjudande från de tidigare ägarna av Cyano Biotech att förlänga förfallodag...

MFN • 05 May 2023 18:56

SIMRIS GROUP AB FÅR SIN STÖRSTA ORDER NÅGONSIN PÅ CIRKA 4,0 MSEK

Simris Group AB (publ), bekräftar att de har fått sin största enskilda order någonsin på fucoxantinrik algbiomassa värd cirka 4,0 MSEK.

MFN • 02 May 2023 12:15

SIMRIS GROUP AB BREDAR DISTRIBUTIONEN AV SINA OMFORMULERADE ALG OMEGA-3 PRODUKTER

Simris Group AB (publ), bekräftar lanseringen av sina nya Omega 3-produkter i USA via Amazon.

MFN • 28 Apr 2023 16:08

KALLELSE TILL ÅRSSTÄMMA I SIMRIS GROUP AB (PUBL)

Simris Group AB (publ), org.nr 556841–9187 (”Bolaget”) håller årsstämma den 29 maj 2023 klockan 10.

MFN • 27 Apr 2023 12:51

SIMRIS GROUP BEKRÄFTAR EN ÖKNING AV SIN FLEXIBLA FINANSIERINGSFACILITET

Simris Group AB (publ), är glada att kunna tillkännage en ökning med upp till €150 000 till sin flexibla finansieringsfacilitet med The Bran...

MFN • 21 Apr 2023 19:58

SIMRIS GROUP AB MEDDELADE IDAG ATT STYRELSEN BESLUTAT ATT FLYTTA BOLAGETS ÅRSSTÄMMA FRÅN DEN 15 MAJ 2023 TILL DEN 29 MAJ 2023

SIMRIS GROUP AB MEDDELADE IDAG ATT STYRELSEN BESLUTAT ATT FLYTTA BOLAGETS ÅRSSTÄMMA FRÅN DEN 15 MAJ 2023 TILL DEN 29 MAJ 2023

MFN • 17 Apr 2023 21:00

SIMRIS GROUP PUBLICERAR ÅRSREDOVISNINGEN FÖR 2022

Simris Group AB ar publicerat sin årsredovisning för verksamhetsåret 2022.

MFN • 17 Apr 2023 20:45

SIMRIS GROUP AB RAPPORTERAR REKORDTILLVÄXT PÅ ALGFARM

Simris Group AB (publ), meddelar idag att sedan återstarten av verksamheten vid sin algfarm i Hammenhög, Sverige i januari, att tillväxttakt...

MFN • 27 Mar 2023 12:00

SIMRIS ALG AB BEKRÄFTAR NAMNBYTE TILL SIMRIS GROUP AB

Simris Alg AB (publ), meddelar idag att företagets namn officiellt har ändrats till Simris Group AB inom det svenska aktiebolagsregistret (B...

MFN • 13 Mar 2023 17:05

Simris Alg ab Signs Partnership Agreement With Lonza Ltd to Promote Its Adc Payload Technology

Simris Alg ab Signs Partnership Agreement With Lonza Ltd to Promote Its Adc Payload Technology

GlobeNewswire • 06 Mar 2023 14:00

KOMMUNIKÉ FRÅN EXTRA BOLAGSSTÄMMA I SIMRIS ALG AB (PUBL)

Simris Alg AB (publ) ("Bolaget") höll extra bolagsstämma den 6 mars 2023.

MFN • 06 Mar 2023 11:30

SIMRIS ALG AB TECKNAR SAMARBETSAVTAL MED LONZA LTD FÖR ATT MARKNADSFÖRA SIN ADC PAYLOAD TEKNOLOGI

• Strategiskt samarbetsavtal för att kommersialisera Simris nya ”payload” plattform för Antibody-Drug Conjugates (ADCs).

MFN • 28 Feb 2023 08:00

SIMRIS ALG AB RESOLVES TO CHANGE NAME OF ITS SUBSIDIARY CYANO BIOTECH GmbH TO SIMRIS BIOLOGICS GmbH

· Simris Alg AB recently proposed to Shareholders to change the name of the parent company from Simris Alg AB to Simris Group AB.

Cision • 23 Feb 2023 09:15

SIMRIS ALG AB BESLUTAR ATT ÄNDRA NAMN PÅ SITT DOTTERBOLAG CYANO BIOTECH GmbH TILL SIMRIS BIOLOGICS GmbH

· Simris Alg AB föreslog nyligen för aktieägarna för att ändra moderbolagets namn från Simris Alg AB till Simris Group AB.

Cision • 23 Feb 2023 09:15

SIMRIS ALG AB CONFIRMS GRANTING OF JAPANESE PATENT COVERING THE MODIFICATION OF MICROCYSTINS

· The patent provides broad protection for a platform technology covering the modification of microcystins;  a novel ADC payload class wi...

Cision • 22 Feb 2023 11:30

SIMRIS ALG AB BEKRÄFTAR BEVILJANDE AV JAPANSKT PATENT SOM TÄCKER MODIFIERING AV MICROCYSTIN

· Patentet ger ett brett skydd för en plattformsteknologi som täcker modifiering av mikrocystiner; en ny ADC-nyttolastklass med ett unikt...

Cision • 22 Feb 2023 11:30

Rättelse: Simris Alg bokslutskommuniké januari - december 2022

Rättelsen avser den svenska versionen av bolagets bokslutskommuniké.

Cision • 15 Feb 2023 16:10

Simris Alg bokslutskommuniké januari - december 2022

Simris Alg bokslutskommuniké januari - december 2022

Cision • 15 Feb 2023 08:00

Simris Alg year-end report January-December 2022

Simris Alg year-end report January-December 2022

Cision • 15 Feb 2023 08:00

Kallelse till extra bolagsstämma i Simris Alg AB (publ)

Notice of extraordinary general meeting of Simris Alg AB (publ) Simris Alg AB (publ), org.

Cision • 01 Feb 2023 20:00

SIMRIS ALG AB FÖRESLÅR NAMNSÄNDRING TILL SIMRIS GROUP AB

Simris Alg AB (publ), meddelar idag att de föreslår att byta namn till Simris Group AB.

Cision • 31 Jan 2023 17:00

SIMRIS ALG AB PROPOSES NAME CHANGE TO SIMRIS GROUP AB

Simris Alg AB (publ), today announces that it proposes to change its name to Simris Group AB.

Cision • 31 Jan 2023 17:00

SIMRIS ALG BEKRÄFTAR EN ÖKNING AV SIN FLEXIBLA FINANSIERINGSFACILITET

Simris Alg AB (publ), tillkännagav idag en ökning på 0,5 miljoner euro till sin flexibla finansieringsfacilitet med The Brand Laboratories, ...

Cision • 24 Jan 2023 09:30

SIMRIS ALG CONFIRMS AN INCREASE TO ITS FLEXIBLE FUNDING FACILITY

Simris Alg AB (publ), today announced a €0.5m increase to its flexible funding facility with The Brand Laboratories, a company associated wi...

Cision • 24 Jan 2023 09:30

SIMRIS ALG LANSERAR SITT NYA, AV EU GODKÄNDA, OMEGA-3 KOSTTILSKOTT I SVERIGE

Simris Alg AB (publ) offentliggjorde idag den svenska lanseringen av sin nya, förbättrade Omega-3-produkt innehållande både EPA och DHA som ...

Cision • 10 Jan 2023 08:00

SIMRIS ALG LAUNCHES ITS NEW EU-APPROVED OMEGA-3 PRODUCT IN SWEDEN

Simris Alg AB (publ) today announced the launch in Sweden of its newly reformulated Omega-3 product containing both EPA and DHA which, for t...

Cision • 10 Jan 2023 08:00

Simris Alg delårsrapport januari - september 2022

Simris Alg delårsrapport januari - september 2022

Cision • 09 Nov 2022 08:00

Simris Alg interim report January-September 2022

Simris Alg interim report January-September 2022

Cision • 09 Nov 2022 08:00

Simris Alg conducts directed share issue

The Board of Directors of Simris ALG AB (publ) ("Simris" or the "Company") has today, with the support of authorization from the Annual Gene...

Cision • 07 Sep 2022 20:20

SIMRIS ALG AQUIRES CYANO BIOTECH IN ACCRETIVE DEAL

Simris Alg AB (publ), today announced the successful completion of its acquisition of Cyano Biotech GmbH, a profitable, privately held Berli...

Cision • 25 Aug 2022 13:15

Simris Alg interim report January-June 2022

Simris Alg interim report January-June 2022

Cision • 17 Aug 2022 08:00

Simris Alg delårsrapport januari - juni 2022

Simris Alg delårsrapport januari - juni 2022

Cision • 17 Aug 2022 08:00

SIMRIS ALG SIGN LETTER OF INTENT TO ACQUIRE CYANO BIOTECH AS A FIRST STEP TOWARDS BIOPHARMA

Simris Alg AB (publ), is pleased to announce that it entered into a binding Letter Of Intent (“LOI”) to acquire 100% of the shares in Cyano ...

Cision • 17 Aug 2022 07:00

SIMRIS ALG TECKNAR AVSIKTSFÖRKLARING AVSEENDE FÖRVARV AV CYANO BIOTECH SOM ETT FÖRSTA STEG MOT BIOPHARMA

Simris Alg AB (publ), meddelar att de ingick en bindande avsiktsförklaring (“LOI”) om att förvärva 100 % av aktierna i Cyano Biotech GmbH de...

Cision • 17 Aug 2022 07:00

Simris Alg presents CEO Letter

Simris Alg AB hereby provides a CEO letter that covers the strategic direction set out by the Board where Simris will enter high profit sect...

Cision • 04 Aug 2022 08:00

Simris Alg announces change of Certified Adviser to Amudova and termination of liquidity guarantee service

Simris Alg AB hereby announces that the company has entered into an agreement with Amudova AB regarding the service as Certified Adviser.

Cision • 19 Jul 2022 08:00

ANNUAL GENERAL MEETING OF SHAREHOLDERS IN SIMRIS ALG AB (PUBL)

The annual general meeting of Simris Alg AB (publ) was held on Wednesday, 25 May 2022.

Cision • 25 May 2022 13:04

Simris Alg AB rights issue is registered – conversion of BTA B to B shares

Simris Alg AB (publ) (“Simris Alg” or the “Company”) has carried out a rights issue of B shares to an amount of approximately SEK 25.

Cision • 16 May 2022 16:00

Final subscription rate of rights issue in Simris Alg AB amounts to 110 percent while the directed share issue and the two issues of warrants have been fully subscribed

The Rights Issue of approximately SEK 25.1 million in Simris Alg AB (publ) (“Simris Alg” or the “Company”), which was announced on March 23,...

Cision • 09 May 2022 20:15

Preliminary subscription rate of rights issue in Simris Alg AB (publ) amounts to approximately 110 percent

The preliminary outcome of the rights issue in Simris Alg AB (publ) (“Simris Alg” or the “Company”), the subscription period of which ended ...

Cision • 05 May 2022 18:15

Kallelse till årsstämma i Simris Alg AB (publ)

Notice of annual general meeting Tid: 25 maj 2022 klockan 11.

Cision • 25 Apr 2022 18:00

Simris Alg interim report January-March 2022

Simris Alg interim report January-March 2022

Cision • 22 Apr 2022 08:00

Simris Alg publishes its annual report for 2021

Simris Alg AB has published its annual report for the 2021 financial year.

Cision • 20 Apr 2022 16:00

Simris Alg publishes investment memorandum regarding Rights Issue

Simris Alg AB (”Simris Alg” or ”the Company”) has produced an investment memorandum regarding the Company’s Rights Issue, which was made pub...

Cision • 20 Apr 2022 08:00

Simris Alg ändrar språk för informationsgivning till engelska

Styrelsen för Simris Alg har beslutat att ändra kommunikationsspråk till engelska till följd av att bolaget har en internationell styrelse d...

Cision • 19 Apr 2022 19:03

Simris Alg tidigarelägger delårsrapport för kvartal 1

Simris Alg meddelar härmed att publiceringen av bolagets delårsrapport för första kvartalet 2022, perioden 1 januari - 31 mars 2022, kommer ...

Cision • 12 Apr 2022 13:00

Simris Alg flyttar fram årsstämman till 25 maj 2022

Simris Alg meddelar idag att styrelsen beslutat att flytta fram bolagets årsstämma till den 25 maj 2022.

Cision • 12 Apr 2022 13:00

Kommuniké från extra bolagsstämma i Simris Alg AB (publ)

Fredagen den 8 oktober 2022 hölls extra bolagsstämma i Simris Alg AB (publ).

Cision • 08 Apr 2022 10:32